93.[20221121]Hypertension in kidney transplant recipients
페이지 정보
작성자 신호식 작성일23-02-03 13:48 조회502회 댓글0건관련링크
- https://youtu.be/Y2rF6YGq_5g 468회 연결
본문
첨부한 자료(유튜브 클립, 참고문헌 등)를 학문적 목적으로만 사용해 주시길 부탁드립니다
Review World J Transplant
. 2022 Aug 18;12(8):211-222. doi: 10.5500/wjt.v12.i8.211.
Hypertension in kidney transplant recipients
Maria-Eleni Alexandrou 1, Charles J Ferro 2, Ioannis Boletis 3, Aikaterini Papagianni 1, Pantelis Sarafidis 4
Affiliations expand
PMID: 36159073 PMCID: PMC9453294 DOI: 10.5500/wjt.v12.i8.211
Free PMC article
Abstract
Kidney transplantation is considered the treatment of choice for end-stage kidney disease patients. However, the residual cardiovascular risk remains significantly higher in kidney transplant recipients (KTRs) than in the general population. Hypertension is highly prevalent in KTRs and represents a major modifiable risk factor associated with adverse cardiovascular outcomes and reduced patient and graft survival. Proper definition of hypertension and recognition of special phenotypes and abnormal diurnal blood pressure (BP) patterns is crucial for adequate BP control. Misclassification by office BP is commonly encountered in these patients, and a high proportion of masked and uncontrolled hypertension, as well as of white-coat hypertension, has been revealed in these patients with the use of ambulatory BP monitoring. The pathophysiology of hypertension in KTRs is multifactorial, involving traditional risk factors, factors related to chronic kidney disease and factors related to the transplantation procedure. In the absence of evidence from large-scale randomized controlled trials in this population, BP targets for hypertension management in KTR have been extrapolated from chronic kidney disease populations. The most recent Kidney Disease Improving Global Outcomes 2021 guidelines recommend lowering BP to less than 130/80 mmHg using standardized BP office measurements. Dihydropyridine calcium channel blockers and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers have been established as the preferred first-line agents, on the basis of emphasis placed on their favorable outcomes on graft survival. The aim of this review is to provide previous and recent evidence on prevalence, accurate diagnosis, pathophysiology and treatment of hypertension in KTRs.
Keywords: Diagnosis; Epidemiology; Hypertension; Kidney transplantation; Physiopathology; Therapy.
Review World J Transplant
. 2022 Aug 18;12(8):211-222. doi: 10.5500/wjt.v12.i8.211.
Hypertension in kidney transplant recipients
Maria-Eleni Alexandrou 1, Charles J Ferro 2, Ioannis Boletis 3, Aikaterini Papagianni 1, Pantelis Sarafidis 4
Affiliations expand
PMID: 36159073 PMCID: PMC9453294 DOI: 10.5500/wjt.v12.i8.211
Free PMC article
Abstract
Kidney transplantation is considered the treatment of choice for end-stage kidney disease patients. However, the residual cardiovascular risk remains significantly higher in kidney transplant recipients (KTRs) than in the general population. Hypertension is highly prevalent in KTRs and represents a major modifiable risk factor associated with adverse cardiovascular outcomes and reduced patient and graft survival. Proper definition of hypertension and recognition of special phenotypes and abnormal diurnal blood pressure (BP) patterns is crucial for adequate BP control. Misclassification by office BP is commonly encountered in these patients, and a high proportion of masked and uncontrolled hypertension, as well as of white-coat hypertension, has been revealed in these patients with the use of ambulatory BP monitoring. The pathophysiology of hypertension in KTRs is multifactorial, involving traditional risk factors, factors related to chronic kidney disease and factors related to the transplantation procedure. In the absence of evidence from large-scale randomized controlled trials in this population, BP targets for hypertension management in KTR have been extrapolated from chronic kidney disease populations. The most recent Kidney Disease Improving Global Outcomes 2021 guidelines recommend lowering BP to less than 130/80 mmHg using standardized BP office measurements. Dihydropyridine calcium channel blockers and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers have been established as the preferred first-line agents, on the basis of emphasis placed on their favorable outcomes on graft survival. The aim of this review is to provide previous and recent evidence on prevalence, accurate diagnosis, pathophysiology and treatment of hypertension in KTRs.
Keywords: Diagnosis; Epidemiology; Hypertension; Kidney transplantation; Physiopathology; Therapy.